Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset receives new US patent for HCV drug
The new patent entitled, ‘Nucleoside Phosphoramidate Prodrugs,’ is related to the composition and matter of PSI-7977 and its diastereomeric mixture indicated for the treatment of hepatitis C virus
The new patent entitled, ‘Nucleoside Phosphoramidate Prodrugs,’ is related to the composition and matter of PSI-7977 and its diastereomeric mixture indicated for the treatment of hepatitis C virus
Under the agreement, Pharmatech will use all its expertise and experience in regulatory affairs to help the Chinese manufacturer to meet the required compliance demanded by the regulatory
Seaside Therapeutics expects to recruit around 150 patients in 25 clinical sites in the US. In the study patients will be randomized to receive either STX209 or placebo.
Currently, the company is developing hGH-CTP in Phase II trial as a treatment for growth harmone deficiency in children. Earlier, Prolor has released interim results from a Phase
The nutrition research program will be conducted in collaboration with a strategic partner, the Institute of Nutraceuticals and Functional Foods (INAF). INAF dedicates all of its research efforts
The launching of the product follows the US Food and Drug Administration’s (FDA) approval of abbreviated new drug application (ANDA) for Levofloxacin tablets. According to the company, Levofloxacin
TH-302 is a novel small molecule tumor selective hypoxia-activated prodrug (HAP) that specifically targets tumor hypoxia and is applicable to a broad range of solid tumors. Earlier, the
BT-061 is a humanized monoclonal antibody that works by activating the body’s T-regulatory cells, a subset of T-cells, strengthening a natural function of the body that prevents excessive
Earlier, following its inspection in March, the FDA issued a list of observed deviations from current Good Manufacturing Practice (GMP). In return, the company responded to the FDA’s
The lawsuit was filed in connection with Sun Pharma‘s submission of abbreviated new drug application (ANDA) seeking marketing rights for the generic versions of Depomed‘s 500mg and 1000mg